Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer

Fig. 5

Evaluation of drug efficacy using xenografts of H2170 cells with amplification of wild-type HER2 and summary of our arguments by schema. A Comparison of tumor size in each drug group and vehicle group in H2170 xenografts. Differences between the two groups were tested with the Wilcoxon rank-sum test. Differences among three groups were tested with the Kruskal-Wallis test and Dunn’s test. Error bars, SD. *P < 0.05 and **P < 0.01. T + P, trastuzumab and pertuzumab; Lp 150, Lapatinib 150 mg/kg. B Appearance of tumors at the time when the mice were sacrificed (day22). C Drug efficacy evaluation using H2170 cells in vitro. IC50, half maximal inhibitory concentration. D Summary of our arguments by schema. HER2, human epidermal growth factor receptor 2; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor

Back to article page